Polygenic risk for schizophrenia and subjective well-being in a general population sample
: Serimaa, Oona; Keltikangas-Järvinen, Liisa; Lyytikäinen, Leo-Pekka; Hietala, Jarmo; Sormunen, Elina; Kähönen, Mika; Raitakari, Olli; Lehtimäki, Terho; Saarinen, Aino
Publisher: CAMBRIDGE UNIV PRESS
: CAMBRIDGE
: 2025
: Psychological Medicine
: PSYCHOLOGICAL MEDICINE
: PSYCHOL MED
: e133
: 55
: 10
: 0033-2917
: 1469-8978
DOI: https://doi.org/10.1017/S0033291725000911
: https://doi.org/10.1017/S0033291725000911
: https://research.utu.fi/converis/portal/detail/Publication/491846757
Background Previous evidence has reported associations of a polygenic risk score for schizophrenia (PRSSCZ) with negative developmental outcomes, such as psychiatric symptoms, adverse health behaviors, and reduced everyday functioning. We now investigated the relationship of PRSSCZ with subjectively experienced well-being.
Methods Participants (n = 1866) came from the prospective population-based Young Finns Study (YFS). Subjective well-being in adulthood was assessed in terms of life satisfaction, optimism, and self-acceptance (when participants were 20-50 years old). A PRSSCZ was calculated based on the most recent genome-wide association study on schizophrenia. Covariates included age, sex, early family environment, adulthood socioeconomic factors, and adulthood health behaviors.
Results The PRSSCZ did not predict any domain of subjective well-being, including life satisfaction, optimism, and self-acceptance. After adding covariates in a stepwise manner or including/excluding participants with diagnosed non-affective psychotic disorders, all the associations remained non-significant. Age- and sex-interaction analyses showed that PRSSCZ was not associated with subjective well-being in either sex or in any age between 20 and 50 years.
Conclusions While high PRSSCZ has been linked to multiple adversities in previous studies, we did not find any association between high PRSSCZ and subjective measures of life satisfaction, optimism, and self-acceptance.
:
This study has been financially supported by the Emil Aaltonen Foundation (grant 220255). The Young Finns Study has been financially supported by the Academy of Finland: grants 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation; Finnish Society of Clinical Chemistry; the Cancer Foundation Finland; pBETTER4U_EU (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you; project number: 101080117); CVDLink (EU grant no. 101137278) and the Jane and Aatos Erkko Foundation.
